Post-earnings recap
Reported
Tue, May 4, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx Pharma's first-quarter earnings report revealed a significant miss on EPS, which contributed to a 4.38% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term outlook. Management's defensive tone suggests they are facing challenges in the current market environment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.03 | N/A | -62.66% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions affecting performance. They did not offer specific guidance for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting market expectations.